{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T20:05:28Z","timestamp":1762459528198},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,10,3]],"date-time":"2017-10-03T00:00:00Z","timestamp":1506988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>End-stage renal disease is associated with mineral and bone disorders. Guidelines recommending therapies should be based on serial assessments of biomarkers, and thus on variations (\u0394), rather than scattered values. We analyzed the correlations between \u0394PTH and \u0394bone biomarkers such as bone-specific alkaline phosphatase (b-ALP), Beta-CrossLaps (CTX), osteocalcin, intact serum procollagen type-1 N-propeptide (P1NP), and tartrate-resistant acid phosphatase 5B (TRAP-5B) at different time-points. In this prospective observational analysis, variations of biomarkers were followed after 6-week (n\u2009=\u2009129), 6-month (n\u2009=\u2009108) and one-year (n\u2009=\u200993) period. Associations between variations were studied by univariate linear regression. Patients followed for one-year period were classified (increaser or decliner) according to variations reaching the critical difference. Over the 6-week period, only \u0394CTX was correlated with \u0394PTH (r\u2009=\u20090.38, p\u2009&lt;\u20090.0001). Over the one-year period, correlations between \u0394PTH and \u0394bone biomarkers became significant (r from 0.23 to 0.47, p\u2009&lt;\u20090.01), except with \u0394TRAP-5b. Correlations between \u0394bone biomarkers were all significant after one-year period (r from 0.31 to 0.68, p\u2009&lt;\u20090.01), except between \u0394b-ALP and \u0394TRAP-5b. In the head-to-head classifications (decliners\/increasers), the percentage of concordant patients was significantly higher over the one-year than the 6-week period. A concordance between \u0394PTH and \u0394bone biomarkers is observed in dialysis patients, but only after a long follow-up.<\/jats:p>","DOI":"10.1038\/s41598-017-12808-3","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T13:31:32Z","timestamp":1506519092000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Variations of parathyroid hormone and bone biomarkers are concordant only after a long term follow-up in hemodialyzed patients"],"prefix":"10.1038","volume":"7","author":[{"given":"Pierre","family":"Delanaye","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Warling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martial","family":"Moonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Smelten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Jouret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Krzesinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Maillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Pottel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,3]]},"reference":[{"key":"12808_CR1","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1038\/ki.2013.254","volume":"84","author":"RN Moorthi","year":"2013","unstructured":"Moorthi, R. N. & Moe, S. M. Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int \n                           84, 886\u2013894 (2013).","journal-title":"Kidney Int"},{"key":"12808_CR2","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.semnephrol.2014.09.004","volume":"34","author":"PU Torres","year":"2014","unstructured":"Torres, P. U., Bover, J., Mazzaferro, S., de Vernejoul, M. C. & Cohen-Solal, M. When, how, and why a bone biopsy should be performed in patients with chronic kidney disease. Semin Nephrol \n                           34, 612\u2013625 (2014).","journal-title":"Semin Nephrol"},{"key":"12808_CR3","doi-asserted-by":"crossref","unstructured":"Vervloet, M. G. & Brandenburg, V. M. Circulating markers of bone turnover. J Nephrol. in press (2017).","DOI":"10.1007\/s40620-017-0408-8"},{"key":"12808_CR4","unstructured":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl S1\u2013130 (2009)."},{"key":"12808_CR5","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","volume":"92","author":"M Ketteler","year":"2017","unstructured":"Ketteler, M. et al. Executive summary of the 2017 KDIGO Chronic Kidney&nbsp;Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters. Kidney Int \n                           92, 26\u201336 (2017).","journal-title":"Kidney Int"},{"key":"12808_CR6","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.clinbiochem.2014.04.007","volume":"47","author":"E Cavalier","year":"2014","unstructured":"Cavalier, E. et al. Inter-method variability in bone alkaline phosphatase measurement: clinical impact on the management of dialysis patients. Clin Biochem \n                           47, 1227\u20131230 (2014).","journal-title":"Clin Biochem"},{"key":"12808_CR7","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.ki.5001606","volume":"70","author":"JC Souberbielle","year":"2006","unstructured":"Souberbielle, J. C. et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int \n                           70, 345\u2013350 (2006).","journal-title":"Kidney Int"},{"key":"12808_CR8","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1093\/ndt\/gft275","volume":"29","author":"P Delanaye","year":"2014","unstructured":"Delanaye, P., Souberbielle, J.-C., Lafage-Proust, M.-H., Jean, G. & Cavalier, E. Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts. Nephrol Dial Transplant \n                           29, 997\u20131004 (2014).","journal-title":"Nephrol Dial Transplant"},{"key":"12808_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.cca.2006.02.029","volume":"371","author":"E Cavalier","year":"2006","unstructured":"Cavalier, E., Delanaye, P., Collette, J., Krzesinski, J.-M. & Chapelle, J.-P. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta \n                           371, 107\u2013111 (2006).","journal-title":"Clin Chim Acta"},{"key":"12808_CR10","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1093\/ndt\/gfg144","volume":"18","author":"H Reichel","year":"2003","unstructured":"Reichel, H., Esser, A., Roth, H. J. & Schmidt-Gayk, H. Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial.Transplant \n                           18, 759\u2013768 (2003).","journal-title":"Nephrol Dial.Transplant"},{"key":"12808_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cca.2012.12.009","volume":"417","author":"P Delanaye","year":"2013","unstructured":"Delanaye, P. et al. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple? Clin Chim.Acta \n                           417, 35\u201338 (2013).","journal-title":"Clin Chim.Acta"},{"key":"12808_CR12","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","volume":"67","author":"SM Sprague","year":"2016","unstructured":"Sprague, S. M. et al. Diagnostic Accuracy of Bone Turnover Markers and Bone Histology in Patients With CKD Treated by Dialysis. Am J Kidney Dis \n                           67, 559\u2013566 (2016).","journal-title":"Am J Kidney Dis"},{"key":"12808_CR13","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/ki.1995.201","volume":"47","author":"A Torres","year":"1995","unstructured":"Torres, A. et al. Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int \n                           47, 1434\u20131442 (1995).","journal-title":"Kidney Int"},{"key":"12808_CR14","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/ki.2014.349","volume":"87","author":"GJ Behets","year":"2015","unstructured":"Behets, G. J. et al. Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int \n                           87, 846\u201356 (2015).","journal-title":"Kidney Int"},{"key":"12808_CR15","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1053\/j.ajkd.2012.12.013","volume":"61","author":"E Cavalier","year":"2013","unstructured":"Cavalier, E., Delanaye, P. & Moranne, O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis \n                           61, 847\u2013848 (2013).","journal-title":"Am J Kidney Dis"},{"key":"12808_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000444890","volume":"43","author":"M Soohoo","year":"2016","unstructured":"Soohoo, M. et al. Changes in Markers of Mineral and Bone Disorders and Mortality in Incident Hemodialysis Patients. Am J Nephrol \n                           43, 85\u201396 (2016).","journal-title":"Am J Nephrol"},{"key":"12808_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.bone.2014.01.016","volume":"61","author":"E Streja","year":"2014","unstructured":"Streja, E. et al. Mortality of combined serum phosphorus and parathyroid hormone concentrations and their changes over time in hemodialysis patients. Bone \n                           61, 201\u2013207 (2014).","journal-title":"Bone"},{"key":"12808_CR18","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/clinchem\/45.8.1347","volume":"45","author":"GR Mundy","year":"1999","unstructured":"Mundy, G. R. & Guise, T. A. Hormonal control of calcium homeostasis. Clin Chem \n                           45, 1347\u20131352 (1999).","journal-title":"Clin Chem"},{"key":"12808_CR19","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2215\/CJN.09580911","volume":"8","author":"G Garrett","year":"2013","unstructured":"Garrett, G., Sardiwal, S., Lamb, E. J. & Goldsmith, D. J. PTH\u2013a particularly tricky hormone: why measure it at all in kidney patients? Clin J Am Soc Nephrol \n                           8, 299\u2013312 (2013).","journal-title":"Clin J Am Soc Nephrol"},{"key":"12808_CR20","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1093\/ndt\/gfh214","volume":"19","author":"C Sanchez","year":"2004","unstructured":"Sanchez, C. et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant \n                           19, 1587\u20131593 (2004).","journal-title":"Nephrol Dial Transplant"},{"key":"12808_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.5414\/CNP68063","volume":"68","author":"G Jean","year":"2007","unstructured":"Jean, G., Chazot, C. & Charra, B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol \n                           68, 63\u201364 (2007).","journal-title":"Clin Nephrol"},{"key":"12808_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.cca.2013.07.016","volume":"425","author":"E Cavalier","year":"2013","unstructured":"Cavalier, E., Lukas, P., Carlisi, A., Gadisseur, R. & Delanaye, P. Aminoterminal propeptide of type I procollagen (PINP) in chronic kidney disease patients: the assay matters. Clin Chim Acta \n                           425, 117\u2013118 (2013).","journal-title":"Clin Chim Acta"},{"key":"12808_CR23","doi-asserted-by":"publisher","first-page":"c112","DOI":"10.1159\/000081552","volume":"98","author":"H Reichel","year":"2004","unstructured":"Reichel, H., Roth, H. J. & Schmidt-Gayk, H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone resorption in chronic hemodialysis patients. Nephron Clin Pract \n                           98, c112\u2013c118 (2004).","journal-title":"Nephron Clin Pract"},{"key":"12808_CR24","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1093\/clinchem\/47.8.1410","volume":"47","author":"R Okabe","year":"2001","unstructured":"Okabe, R. et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem \n                           47, 1410\u20131414 (2001).","journal-title":"Clin Chem"},{"key":"12808_CR25","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.clinbiochem.2012.01.018","volume":"45","author":"G Jean","year":"2012","unstructured":"Jean, G. et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem \n                           45, 436\u2013439 (2012).","journal-title":"Clin Biochem"},{"key":"12808_CR26","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","volume":"22","author":"S Vasikaran","year":"2011","unstructured":"Vasikaran, S. et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int \n                           22, 391\u2013420 (2011).","journal-title":"Osteoporos Int"},{"key":"12808_CR27","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1007\/s00223-008-9127-4","volume":"82","author":"K Shidara","year":"2008","unstructured":"Shidara, K. et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int \n                           82, 278\u2013287 (2008).","journal-title":"Calcif Tissue Int"},{"key":"12808_CR28","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2265.2008.03187.x","volume":"69","author":"S Yamada","year":"2008","unstructured":"Yamada, S. et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol \n                           69, 189\u2013196 (2008).","journal-title":"Clin Endocrinol"},{"key":"12808_CR29","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.2215\/CJN.09470913","volume":"9","author":"HH Malluche","year":"2014","unstructured":"Malluche, H. H., Davenport, D. L., Cantor, T. & Monier-Faugere, M. C. Bone Mineral Density and Serum Biochemical Predictors of Bone Loss in Patients with CKD on Dialysis. Clin J Am Soc Nephrol \n                           9, 1254\u20131262 (2014).","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12808-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12808-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T11:38:14Z","timestamp":1671795494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-12808-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,3]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["12808"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-12808-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,3]]},"assertion":[{"value":"30 June 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Pierre Delanaye and Etienne Cavalier are consultants for IDS company. Etienne Cavalier is consultant for Diaosrin. These companies have not been involved in the current research. Other authors have no conflict of interest to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12623"}}